Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Ting Wei Wang, Ming Sheng Hsu, Yi Hui Lin, Hwa Yen Chiu, Heng Sheng Chao, Chien Yi Liao, Chia Feng Lu, Yu Te Wu, Jing Wen Huang*, Yuh Min Chen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

In the context of non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), this research evaluated the prognostic value of CT-based radiomics. A comprehensive systematic review and meta-analysis of studies up to April 2023, which included 3111 patients, was conducted. We utilized the Quality in Prognosis Studies (QUIPS) tool and radiomics quality scoring (RQS) system to assess the quality of the included studies. Our analysis revealed a pooled hazard ratio for progression-free survival of 2.80 (95% confidence interval: 1.87–4.19), suggesting that patients with certain radiomics features had a significantly higher risk of disease progression. Additionally, we calculated the pooled Harrell’s concordance index and area under the curve (AUC) values of 0.71 and 0.73, respectively, indicating good predictive performance of radiomics. Despite these promising results, further studies with consistent and robust protocols are needed to confirm the prognostic role of radiomics in NSCLC.

Original languageEnglish
Article number3542
JournalCancers
Volume15
Issue number14
DOIs
StatePublished - Jul 2023

Keywords

  • computed tomography
  • EGFR tyrosine kinase inhibitors
  • non-small cell lung cancer
  • radiomics
  • treatment outcome

Fingerprint

Dive into the research topics of 'Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis'. Together they form a unique fingerprint.

Cite this